The net effect of type I interferon (IFN-I) signaling on tumor control depends on various factors, including the potential engagement of adaptive anticancer immunity. New findings delineate a targetable epigenetic mechanism by which suboptimal IFN-I signaling promotes tumor progression in the context of cancer stem cell expansion and immunoevasion.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Cell Death Discovery Open Access 26 November 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O’Garra, A. Nat. Rev. Immunol. 15, 87–103 (2015).
Kroemer, G., Galassi, C., Zitvogel, L. & Galluzzi, L. Nat. Immunol. 23, 487–500 (2022).
Musella, M. et al. Nat. Immunol. https://doi.org/10.1038/s41590-022-01290-3 (2022).
Sistigu, A. et al. Nat. Med. 20, 1301–1309 (2014).
Yamazaki, T. et al. Nat. Immunol. 21, 1160–1171 (2020).
Rodriguez-Ruiz, M. E. et al. Oncoimmunology 8, e1655964 (2019).
Weichselbaum, R. R. et al. Proc. Natl Acad. Sci. USA 105, 18490–18495 (2008).
Palucka, A. K. & Coussens, L. M. Cell 164, 1233–1247 (2016).
Vanpouille-Box, C., Demaria, S., Formenti, S. C. & Galluzzi, L. Cancer Cell 34, 361–378 (2018).
Hopfner, K. P. & Hornung, V. Nat. Rev. Mol. Cell Biol. 21, 501–521 (2020).
Rehwinkel, J. & Gack, M. U. Nat. Rev. Immunol. 20, 537–551 (2020).
Bayik, D. & Lathia, J. D. Nat. Rev. Cancer 21, 526–536 (2021).
L.G. declares having held research contracts with Lytix Biopharma and Promontory, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options. G.K. declares having held research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sotio, Tollys, Vascage and Vasculox/Tioma, has received consulting/advisory honoraria from Reithera, is on the Board of Directors of the Bristol Myers Squibb Foundation France, is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio, and is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders, including patents licensed to Bayer (WO2014020041-A1, WO2014020043-A1), Bristol-Myers Squibb (WO2008057863-A1), Osasuna Therapeutics (WO2019057742A1), PharmaMar (WO2022048775-A1), Raptor Pharmaceuticals (EP2664326-A1), Samsara Therapeutics (GB202017553D0 and GB202017030D0), and Therafast Bio (EP3684471A1).
About this article
Cite this article
Galluzzi, L., Kroemer, G. Immuno-epigenetic escape of cancer stem cells. Nat Immunol 23, 1300–1302 (2022). https://doi.org/10.1038/s41590-022-01293-0
This article is cited by
Cell Death Discovery (2022)